By using the body's own immune system to kill tumor cells, immune cell therapy is anticipated to be a breakthrough strategy to "cure" many types of cancer. Among them, chimeric antigen receptor T-cell immunotherapy (CAR-T) has achieved remarkable results in the treatment of various hematological malignancies. As of 2022, seven CAR-T cell therapy products have been launched globally, including three in China.

The long journey of every CAR-T cell therapy begins with steady steps in performing basic research designed for repeatability. The research process generally includes CAR molecule design, lentiviral packaging, CAR-T cell construction, in vitro and in vivo killing assay, cytotoxicity tests, and more. However, unlike small molecule or antibody drugs, CAR-T is a "live" cell-based drug. In order to build effective and stable CAR-T cells, many factors need to be fully considered, such as rational design of CAR molecular structure, the exploration of T cell transfection conditions, identification of CAR-T cells, and confirmation of purity and potency.

Based on over 16 years of research experience developing cell and animal models for tumor immunology research, Cyagen has built a one-stop service platform for in vivo and in vitro CAR-T cell therapy research. The platform is available to researchers worldwide, which includes scFv sequence screening, CAR molecular design, and full-process services to develop the foundational research for your CAR-T cell therapy. The comprehensive services offered help streamline the efficiency and accuracy of CAR-T/NK research and related fields.

One-stop service platform for CAR-T cell therapy research

Our one-stop platform provides:

1. Viral vector manufacturing

★CAR design
★Lentiviral packaging and optimization
★CAR-T cell construction

2. Tumor Model Construction Platform

★Target cell construction
★C-NKG Severe Immunodeficient Mouse Model
★CDX mouse tumor model
★Humanized model of PBMC/HSC immune system

3. In vitro pharmacodynamic evaluation

★In vitro killing function evaluation of CAR-T cells
★Cytokine detection
★Functional experiments such as cell proliferation/apoptosis/migration/invasion

4. In vivo pharmacodynamic evaluation

★Construction of CDX C-NKG mouse and CDX PBMC/HSC C-NKG mouse models
★Pharmacodynamic evaluation of CAR-T/TCR-T/NK/TIL cells
★Immunohistochemistry (IHC), HE staining, lymphocyte infiltration analysis

How can Cyagen accelerate your CAR-T cell therapy research?

Project Type

Project Technical Difficulties

The Service Advantages of Cyagen Platform

Target cell construction

Difficulty in selecting target cell types

Rich target cell library, with tumor cells/CHO/HEK293 cells overexpressing various targets

The expression level of the target is not high enough

Experience with 500+ projects for stable transfer plant construction

CAR lentivirus packaging

Lack of experience in CAR molecular structure design

Rich experience in designing CAR molecules with multiple targets

Low virus titer and difficult purification

High-quality lentiviral packaging, referenced by multiple publications

CAR-T/NK cell construction

Difficulty in culturing T/NK cells

16+ years of primary cell culture experience

It is time-consuming to assess the transfection conditions of T/NK cells; the identification of cells after transfection is difficult

An optimized protocol for fully summarizing the transfection parameters of human/murine immune cells

In vitro killing assay

Difficult to choose evaluation indicators

Mature in vitro pharmacodynamic experimental platform

Data analysis

Professional data analyst